The 12th Asian Conference on Clinical Pharmacy will be held July 7-9, 2012, at the Hong Kong Convention and Exhibition Centre.
The 12th Asian Conference on Clinical Pharmacy will be held July 7-9, 2012, at the Hong Kong Convention and Exhibition Centre. Approximately 1,200 to 1,400 delegates are expected to be in attendance.
This year, the conference is co-organized by the School of Pharmacy, Chinese University of Hong Kong, and the Chinese Pharmaceutical Association.
The theme for this year’s conference is “Citius, Altius, Fortius: Appraising Clinical Excellence, Nurturing Eminent Practice.” “Citius, Altius, Fortius” are Latin words meaning “Faster, Higher, Stronger.”
2012 is the year of the London Olympic Games. According to the organizers, “like Olympic athletes, pharmacists need to maintain high competency and commitment in our profession to ensure medication safety. We have to equip ourselves to reach clinical excellence.”
For more information, visit www.accp2012.org. Or contact the conference secretariat: (852) 2155 8557/(852) 3153 4374 or email: info@accp2012.org.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More